Key Figures

2021120201
Earnings
Mio. Euro
Mio. Euro
Sales revenue
1,7

8,5

Other income
0,6

1,1

Operating expenses
(27,9)

(27,9)

Operating result
(25,6)

(18,3)

Earnings before tax
(26,1)

(18,4)

Net loss for the period
(26,1)

(18,4)

Earnings per share in EUR
(0,80)

(0,61)


Balance sheet as of 30.11.
Total assets
21,7

19,6

Cash and cash equivalents
6,1

5,0

Equity
6,7

12,9

Equity ratio2 in %
30,8

65,7


Cash flow
from operating activities
(26,6)

(17,9)

from investing activities
(1,4)

(1,3)

from financing activities
29,1

14,3


Employees
Employees as of 30.11.3
96

84


  • 1 The reporting period begins on 1 December and ends on 30 November

  • 2 Equity / total assets

  • 3 Including members of the Executive Management Board

Outlook

Guidance 2022 EUR mrev. guidance 10/22
Sales revenue and other income

7.5 – 9.5

18.5 – 20.5

Operating expenses
41.0 – 45.0

35.0 – 39.0

Operating result (EBIT)
(32.5) – (36.5)

(16.0) – (20.0)

Total funding requirement1

33.0 – 37.0

8.0 – 11.0

Funds required per month1

2.8 – 3.1

0.6 – 0.9

  • 1 Not including any corporate actions

© Heidelberg Pharma AG. All rights reserved.